US 2022/0033509 A1 · CHIMERIC ANTIGEN RECEPTOR

Abstract

The present invention provides a chimeric antigen receptor (CAR) which binds a low density target antigen, which comprises a Fab antigen binding domain. The invention also relates to cells expressing such a CAR and their use in the treatment of disease.

Claims22

Dependent claims

A chimeric antigen receptor (CAR) which binds B cell maturation antigen (BCMA), wherein the CAR comprises a Fab antigen binding domain.

Dependencies are inferred from the claim text.

Facts

Application

17/279,874Filed 26 Sep 2019

Priority

GB 1815775.027 Sep 2018

Published

3 Feb 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification22 codes

C07K 14/7051
Immunoglobulin superfamily: t-cell receptor -CD3 complex
C07K 16/2878
Against receptors, cell surface antigens or cell surface determinants: against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]

Abstract

Claims22

Dependent claims

A chimeric antigen receptor (CAR) which binds B cell maturation antigen (BCMA), wherein the CAR comprises a Fab antigen binding domain.

Dependencies are inferred from the claim text.

Chimeric antigen receptor

Life of this patent

Abstract

Claims22

Chimeric antigen receptor

Life of this patent

Abstract

Claims22